A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1343 participants.
Also called NCT04197479
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,343 participants
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Registry
-
NCT04197479
-
- Other papers using this trial's data
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT04197479. Randomized; quadruple masking; primary purpose treatment. Start 2019-12-16 (actual); primary completion 2023-01-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
- Acronym
- MAESTRO-NAFLD1
- Condition
- Non-Alcoholic Fatty Liver Disease
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Resmetirom
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct04197479- Content hash
87da3871c58dd446a25b27a29321881aedaa9cfbdaac2e77bd1d5dff57288f4a